Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use

作者：Satish K. Garg, Satish K. Garg, Halis K. Akturk, Samita Garg, Samita Garg, Roy W. Beck, Natalie J. Bellini, Petter Bjornstad, Anders L. Carlson, Jim Carroll, Kelly Close, Christophe De Block, Klemen Dovc, Gregory P. Forlenza, Francesco Giorgino, Julie Heverly, I Hirsch, Mareda Lewer, Brynn E. Marks, Chantal Mathieu, Revital Nimri, Christie Beatson, Kirsten Nørgaard, David O'Neal, Francisco J. Pasquel, Moshe Phillip, Sarit Polsky, Banshi Saboo, Viral N. Shah, Hui Shao, J L Sherr, Janet K. Snell-Bergeon, Kohjiro Ueki, T Battelino · 发表于：Diabetes Technology & Therapeutics · 年份：2026 · DOI：10.1177/15209156261449879 · 被引用次数：1 · 研究领域：Diabetes Treatment and Management、Diabetes Management and Research、Pancreatic function and diabetes

Among the most impactful therapeutic advances in the management of diabetes over the past two decades has been the development of incretin-based therapies, specifically glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and in combination with glucose-dependent insulinotropic polypeptide (GIP) RAs. Since the introduction of exenatide in 2005, a growing number of these drugs has transformed the management of type 2 diabetes (T2D). Their pleiotropic effects include weight loss, reduced insulin resistance, improved glucose regulation, and reductions in known risk markers for diabetic kidney disease and cardiovascular disease. To date, these important noninsulin glucose-lowering therapies have only received regulatory approval for use in T2D, obesity, sleep apnea, and metabolic dysfunction-associated steatohepatitis with moderate-advanced fibrosis, supported by randomized controlled trials (RCTs) and real-world data that demonstrate efficacy and safety. Regulatory approval for use of weekly GLP-1 and GLP-1/GIP RAs in type 1 diabetes (T1D) has not yet been achieved, in part because of the limited number of inconsistent, small-scale, RCTs and real-world studies for glycemic impacts of these agents in T1D. Larger RCTs are ongoing or planned in participants with T1D. Potential safety risks include hypoglycemia and hyperglycemia-related ketosis in T1D after initiation of GLP-1/GIP RA drugs. While RCTs are ongoing to further investigate GLP-1 and GLP-1/GIP RA agents as adjunct the...